Ser122

Site Information
RIQEQEssGEEDsDL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449053

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 15 ) , [32P] ATP in vitro ( 15 ) , [32P] bio-synthetic labeling ( 61 ) , immunoprecipitation ( 15 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ) , mutation of modification site ( 60 , 61 ) , phospho-antibody ( 60 ) , phosphoamino acid analysis ( 61 ) , western blotting ( 15 , 61 )
Disease tissue studied:	breast cancer ( 3 , 8 , 9 , 16 , 17 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 8 ) , cervical cancer ( 59 ) , cervical adenocarcinoma ( 59 ) , esophageal cancer ( 35 , 36 ) , leukemia ( 22 , 44 , 45 , 46 , 47 ) , acute myelogenous leukemia ( 22 ) , chronic myelogenous leukemia ( 44 , 45 , 46 , 47 ) , liver cancer ( 41 ) , hepatocellular carcinoma, surrounding tissue ( 31 ) , lung cancer ( 11 , 57 ) , non-small cell lung adenocarcinoma ( 11 ) , lymphoma ( 10 , 51 ) , Burkitt's lymphoma ( 10 ) , follicular lymphoma ( 10 ) , mantle cell lymphoma ( 10 ) , ovarian cancer ( 8 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 28 ) , 293 (epithelial) [AT1 (human), transfection] ( 27 ) , 293 (epithelial) ( 37 ) , 293E (epithelial) ( 24 ) , 786-O (renal) [VHL (human), transfection] ( 4 ) , 786-O (renal) ( 4 ) , A498 (renal) ( 30 ) , BJAB (B lymphocyte) ( 10 ) , breast ( 1 , 8 ) , BT-20 (breast cell) ( 17 ) , BT-474 (breast cell) ( 3 ) , BT-549 (breast cell) ( 17 ) , Chang liver (cervical) ( 50 ) , COS (fibroblast) ( 60 , 61 ) , endothelial-aorta ( 18 ) , esophagus ( 35 , 36 ) , FL-318 (B lymphocyte) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 20 ) , Flp-In T-Rex-293 (epithelial) ( 20 ) , GM00130 (B lymphocyte) ( 29 ) , HCC1937 (breast cell) ( 17 ) , HCT116 (intestinal) ( 38 ) , HEK293T (epithelial) ( 5 , 39 , 40 , 55 ) , HeLa (cervical) ( 7 , 14 , 23 , 26 , 32 , 38 , 48 , 49 , 58 ) , hepatocyte-liver ( 31 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 9 ) , HMLER ('stem, breast cancer') ( 9 ) , HUES-9 ('stem, embryonic') ( 25 ) , JEKO-1 (B lymphocyte) ( 10 ) , JHH-5 (hepatic) ( 41 ) , Jurkat (T lymphocyte) ( 12 , 33 , 34 , 42 , 52 , 53 ) , K562 (erythroid) ( 14 , 32 , 43 , 44 , 45 , 46 , 47 ) , KG-1 (myeloid) ( 22 ) , lung ( 11 , 57 ) , MCF-7 (breast cell) ( 3 , 17 ) , MDA-MB-231 (breast cell) ( 17 ) , MDA-MB-468 (breast cell) ( 17 ) , NCEB-1 (B lymphocyte) ( 10 ) , NCI-H460 (pulmonary) ( 38 ) , OCI-ly1 (B lymphocyte) ( 10 ) , ovary ( 8 ) , platelet-blood ( 54 ) , Raji (B lymphocyte) ( 10 ) , RAMOS (B lymphocyte) ( 10 ) , REC-1 (B lymphocyte) ( 10 , 51 ) , SKBr3 (breast cell) ( 16 ) , spermatozoa ( 15 ) , SU-DHL-4 (B lymphocyte) ( 10 ) , T lymphocyte-blood ( 19 ) , UPN-1 (B lymphocyte) ( 10 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Kinases, in vitro:	CK2A1 (human) ( 61 )
Treatments:	antibody ( 19 ) , ischemia ( 8 ) , quinalizarin ( 5 )

Downstream Regulation
Effects of modification on PPP1R2:	intracellular localization ( 61 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
4	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
5	Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23 25278378 Curated Info
6	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
7	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
8	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
9	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
10	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
11	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
12	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
13	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
14	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
15	Korrodi-Gregório L, et al. (2013) Identification and characterization of two distinct PPP1R2 isoforms in human spermatozoa. BMC Cell Biol 14, 15 23506001 Curated Info
16	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
17	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
18	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
19	Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86 22499768 Curated Info
20	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
21	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
22	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
23	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
24	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
25	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
26	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
27	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
28	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
29	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
30	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
31	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
32	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
33	Guo A (2009) CST Curation Set: 8004; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
34	Guo A (2009) CST Curation Set: 8005; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
35	Gu T (2009) CST Curation Set: 7111; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
36	Tucker M (2009) CST Curation Set: 7089; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
37	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
38	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
39	Tucker M (2009) CST Curation Set: 6221; Year: 2009; Biosample/Treatment: cell line, 293T/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
40	Tucker M (2009) CST Curation Set: 6218; Year: 2009; Biosample/Treatment: cell line, 293T/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
41	Tucker M (2009) CST Curation Set: 5961; Year: 2009; Biosample/Treatment: cell line, JHH-5/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
42	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
43	Stokes M (2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
44	Stokes M (2008) CST Curation Set: 4388; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
45	Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
46	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
47	Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
48	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
49	McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80 18212344 Curated Info
50	Sui S, et al. (2008) Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics 8, 2024-34 18491316 Curated Info
51	Gu T (2008) CST Curation Set: 3978; Year: 2008; Biosample/Treatment: cell line, REC-1/untreated; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
52	Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
53	Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
54	Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34 18088087 Curated Info
55	Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204 17287340 Curated Info
56	Gu T (2007) CST Curation Set: 2234; Year: 2007; Biosample/Treatment: cell line, RSK2-1/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
57	Cherry J (2006) CST Curation Set: 2165; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
58	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info
59	Leach C, Shenolikar S, Brautigan DL (2003) Phosphorylation of phosphatase inhibitor-2 at centrosomes during mitosis. J Biol Chem 278, 26015-20 12697755 Curated Info
60	Sakashita G, et al. (2003) Regulation of type 1 protein phosphatase/inhibitor-2 complex by glycogen synthase kinase-3beta in intact cells. J Biochem (Tokyo) 133, 165-71 12761178 Curated Info
61	Kakinoki Y, Somers J, Brautigan DL (1997) Multisite phosphorylation and the nuclear localization of phosphatase inhibitor 2-green fluorescent protein fusion protein during S phase of the cell growth cycle. J Biol Chem 272, 32308-14 9405437 Curated Info